Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $3.08, but opened at $3.24. Autolus Therapeutics shares last traded at $3.07, with a volume of 285,730 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $7.00 to $7.60 in a research report on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 11th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Trading Down 1.3 %

The stock has a market capitalization of $808.93 million, a PE ratio of -2.53 and a beta of 2.04. The firm has a 50-day moving average price of $3.91 and a 200-day moving average price of $3.99.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the company earned ($0.26) EPS. Sell-side analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AUTL. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at about $43,000. Capstone Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the third quarter valued at about $51,000. Daiwa Securities Group Inc. raised its stake in shares of Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares during the last quarter. Herbst Group LLC purchased a new stake in shares of Autolus Therapeutics during the third quarter worth about $91,000. Finally, Bayesian Capital Management LP bought a new stake in shares of Autolus Therapeutics in the first quarter worth about $100,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.